Navigation Links
Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy
Date:5/27/2008

s performed after a minimum of 5-years of follow up. The study showed a significant improvement in 5-year DFS that was demonstrated in the TAC arm over the FAC arm, with 91% and 86% patients, respectively, alive and disease free (HR 0.66, 95% CI 0.46-0.94, p=0.0202). The OS data are immature; estimated 5-year OS is 97% for TAC and 95% for FAC (HR 0.72, 95% CI 0.40-1.30, p=0.2677). The safety results have been already published (Martin et al (2006), Ann Oncol 17: 1205-12) TAC produced significantly more hematological adverse reactions than FAC. Primary prophylaxis with G-CSF reduced the rate of neutropenic fever. No toxic deaths were reported.

"First of all, I would like to congratulate the patients and my fellow investigators for having the courage to participate in this innovative trial in a purely node-negative patient population. This study showed that the TAC regimen improves Disease Free Survival in women with high risk node-negative breast cancer," said GEICAM Chair and principal investigator of the 9805 study, Prof. Miguel Martin.

About the Study

The GEICAM 9805/Target-0 trial was initiated as a complementary study to BCIRG 001/TAX 316, a study that enrolled women with node-positive early stage breast cancer.

From December 2001 to March 2003, 1059 patients aged 18-71, with T1-T3, N0, M0 operable breast cancer and at least one high-risk St Gallen 1998 criterion (patient age <35 years, tumor grade II/III, tumor size >2 cm, or hormone-receptor negative tumor) were enrolled in the study; 1047 patients were eligible. Patients from Spain as well as Germany and Poland were stratified by institution and menopausal status and randomized after surgery to receive either TAC (docetaxel 75 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2) or FAC (5-fluorouracil 500 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2) every 3 weeks for 6 cycles. Radiotherapy was mandatory after conservative surgery and recommended for patients with tu
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
2. Early Esophageal Cancer and Pre-Cancer Eliminated With Non-Surgical Treatment Combination
3. AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients
4. TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial
5. Starting Flu Vaccination in August Could Help Protect Nearly 11 Million More Children During Scheduled Doctors Visits
6. Data Show Preoperative Assessment of Breast Cancer Patients Enables Early Diagnosis, Successful Treatment of Lymphedema
7. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
8. Gene Therapy Provides Vision to People who Were Nearly Blind
9. Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
10. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
11. Study Shows Once-Yearly Reclast Better than Risedronate at Increasing Bone Mass in Patients With Osteoporosis Caused by Glucocorticoids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... , April 16, 2015 Today, Kenneth ... Merck & Co., Inc., was elected chairman of the Board ... today,s Board meeting, PhRMA,s president and CEO John J. ... 1, 2016.  New Officers Elected to PhRMA ... and succeeds Ian C. Read , chairman and CEO ...
(Date:4/16/2015)... April 16, 2015  Rosewind Corporation (OTCMKTS: RSWN) ... merger with a newly formed specialty healthcare company ... on addressing urological disorders. The merged company, which ... has commenced operations and incorporates the pipeline assets ... Company,s strategy is to build a late-stage and ...
(Date:4/16/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/qvd3lm/cancer_growth ) ... Growth Inhibitors Market & Clinical Pipeline Analysis " ... growth inhibitors market shows overlapping boundaries due to ... For instance, a tyrosine kinase may be a ... have same inhibitory molecule. On the other hand, ...
Breaking Medicine Technology:Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 3Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 4Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 5Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 2Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 3Global Cancer Growth Inhibitors Market & Clinical Pipeline Analysis 2015 2Global Cancer Growth Inhibitors Market & Clinical Pipeline Analysis 2015 3
... 28, 2011 Uroplasty, Inc. (NASDAQ: UPI ), ... proprietary products to treat voiding dysfunctions, today reported financial results ... 2011. Global sales grew 53% to $4.7 million ... with $3.0 million in the fiscal first quarter a year ...
... 28, 2011 Codexis, Inc. (Nasdaq: CDXS ... wholly-owned by Italy,s Gruppo Mossi & Ghisolfi ("M&G Group"), ... sustainable detergent alcohols for use in the household products ... alcohols from cellulosic (non-food) biomass. Detergent alcohols ...
Cached Medicine Technology:Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012 2Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012 3Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012 4Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012 5Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012 6Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012 7Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012 8Codexis and Chemtex to Collaborate on Sustainable Detergent Alcohols for the Household Products Market 2Codexis and Chemtex to Collaborate on Sustainable Detergent Alcohols for the Household Products Market 3Codexis and Chemtex to Collaborate on Sustainable Detergent Alcohols for the Household Products Market 4
(Date:4/17/2015)... April 17, 2015 Representatives Jim Himes ... and Treatment Act HR 1849 in congress on April ... and treatment for patients with the genetic disease. ... past, would be the first to create a federally ... treatment of hereditary hemorrhagic telangiectasia. This would effectively prevent ...
(Date:4/17/2015)... 17, 2015 As a board-certified orthopedic ... new offering of platelet-rich plasma (PRP) and ... is known for its world-class care of injury-caused ... surgical experience lacking in many other physicians offering regenerative ... are utilized for pain management and rehabilitation. Dr. Meier ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Most dental ... dental restoration units are made overseas by foreign dental ... domestic labs remain unregulated in more than 40 states ... National Association of Dental Laboratories has created ... raise awareness among patients about the consequences that could ...
(Date:4/17/2015)... Baptist Health and The University of Texas MD ... to transform oncology care in northeast Florida and southeast ... a joint cancer program to enhance patient access to ... Anderson Cancer Center is anticipated to open in the ... coordinated, multidisciplinary cancer care for adults in the region. ...
(Date:4/17/2015)... York, NY (PRWEB) April 17, 2015 ... collaborating with a multicenter team of U.S. and ... of bacteria yet in humans among an isolated ... jungles of Venezuela. Bacterial diversity in the Yanomami, ... found to be nearly double that of people ...
Breaking Medicine News(10 mins):Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3Health News:National Association Urges Transparency in Dental Industry 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 3
... devouring billions of dollars globally, Alzheimer,s disease is the ... Although intensely investigated over the last three decades using ... not been found. While many research "breakthroughs" have ... does the promised "cure" still seem to elude scientists? ...
... (HealthDay News) -- Good news for high-mileage runners: They may be ... because variations in diet are less likely to affect them, researcher ... grouped according to the distance they run each day: less than ... to 4 km); 2.4 to 3.7 miles (4 to 6 km); ...
... published research shows that more patients with end-stage ... hemodialysis as their initial kidney replacement therapy over ... the study now available in Arthritis Care ... College of Rheumatology (ACR), also found that African ...
... device that combines two microimaging technologies can reveal ... biological activities that, in coronary arteries, could indicate ... of clots in arterial stents. In their ... Massachusetts General Hospital (MGH) investigators describe using an ...
... Special Surgery physician-scientists who focus on arthritis, lupus, vasculitis ... to Chicago this week to share their recent findings ... College of Rheumatology (ACR). Special Surgery investigators will ... care. Of the meeting,s highlights, results from the nine-year ...
... appear to be stopping anti-TNF medications before surgery, but may ... a new study by researchers at Hospital for Special Surgery. ... diseases, including rheumatoid arthritis, and better timing of withdrawal prior ... "We need to do more studies to see ...
Cached Medicine News:Health News:New study challenges accepted approaches to research in senile dementia (Alzheimer's disease) 2Health News:New study challenges accepted approaches to research in senile dementia (Alzheimer's disease) 3Health News:Runners Can Relax About Holiday Feasting: Study 2Health News:Most lupus nephritis patients with end-stage renal disease opt for hemodialysis therapy 2Health News:Combined arterial imaging technology reveals both structural and metabolic details 2Health News:Hospital for special surgery physician-scientists share advances in rheumatology research 2Health News:Hospital for special surgery physician-scientists share advances in rheumatology research 3Health News:Hospital for special surgery physician-scientists share advances in rheumatology research 4Health News:Hospital for special surgery physician-scientists share advances in rheumatology research 5Health News:Hospital for special surgery physician-scientists share advances in rheumatology research 6Health News:Tweaking withdrawal of rheumatoid arthritis medications before surgeries may reduce disease flares 2Health News:Tweaking withdrawal of rheumatoid arthritis medications before surgeries may reduce disease flares 3
The RU is a low profile implantable bipolar tined permanent pacing lead for stimulation of either the atrium (J model) or the ventricle (straight model)....
The Petite leads are low profile (4.8F lead body diameter) implantable endocardial pacing leads which are manufactured using a new proprietary hexafilar coil for permanent stimulation of the ventricl...
The Vitatron Excellence S+ lead series are endocardial leads providing excellent reliability and optimal pacing characteristics....
... Impulse II lead series are silicon ... extend the longevity of the pacemaker ... The high impedance of the lead ... electrode surface, combined with the elution ...
Medicine Products: